Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02151006
Other study ID # Sub 2
Secondary ID
Status Completed
Phase Phase 3
First received May 28, 2014
Last updated May 16, 2015
Start date May 2014
Est. completion date May 2015

Study information

Verified date May 2015
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority Egypt: Ministry of Higher Education
Study type Interventional

Clinical Trial Summary

140 women with expected poor ovarian response undergoing IVF/ICSI will be randomly divided into 2 groups using computer generated random numbers . Group 1 ( study group) will receive DHEA 25 mg ( DHEA 25mg, Natrol , USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle. Group 2 ( control group) will not receive DHEA. Patients included in the study will be subjected to full history taking and clinical examination. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm.

All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin (HMG) stimulation until the day of (Human chorionic gonadotrophin (HCG) administration. On the day of HCG administration, ovarian ultrasound scan will be performed using a transvaginal probe. Oocytes will be aspirated 34-36 hours after HCG administration. Oocytes will be fertilized and embryos will be transferred. Both groups will be compared regarding the proportion of pregnancy.


Description:

The study will be conducted in Cairo university hospitals and Dar Al-Teb Infertility and Assisted conception center, Giza Egypt. All patients attending the centre will be evaluated for their expected ovarian response.Patients fulfilling the Bologna criteria definition of poor ovarian response will be invited to participate in the study and to sign informed consent forms. The invitation will include a clear full explanation of the study.

140 women will be randomly divided into 2 groups using computer generated random numbers. Group 1 ( study group) will include 70 women who will receive DHEA 25 mg t.d.s ( DHEA®, Natrol , USA) twice daily for 12 weeks before starting IVF/ICSI cycle. Group 2 will include 70 women who will not receive DHEA and will serve as the control group. All women fulfilling the inclusion criteria will be invited to participate in the study. A written informed consent will be taken and only women signing the consent will be included in the study.

Patients included in the study will be subjected to full history taking and clinical examination including general, abdominal and gynecological examination. This will be followed by a vaginal ultrasound scan to assess uterus, ovaries and any pelvic masses.

On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm.

The stimulation protocol will start on day 2 using 450-300 IU HMG ( Merional® IBSA, Lugano, Switzerland) and GnRH antagonist, cetrorelix (Cetrotide® Merck Serono, Darmstadt, Germany) 0.025 mg daily. Gonadotropins will be administered for 4 to 5 days, after which the dose will be adjusted according to the ovarian response. The ovarian response will be monitored by transvaginal ultrasound and serum E2 levels. When three or more follicles reached a maximum diameter of 16 mm, highly purified HCG 5000 or 10,000 IU (Choriomon ®IBSA) will be administered. The procedure will be cancelled if less than 3 follicles 16 mm in size are present 12 days after starting gonadotropins despite doses reaching 450 IU. The cycle will be also cancelled if there is risk of ovarian hyperstimulation like massive ovarian enlargement or serum estradiol exceeds 3000pg/L Transvaginal oocyte retrieval will be performed 34-36 h after the administration of HCG. Oocytes will be fertilized either via IVF or ICSI based on the couple's history. Fertilization will be assessed 16-18 h after IVF or ICSI . Embryos will be transferred on Day 3 or 5. Vaginal tablets containing progesterone (Prontogest® IBSA) 400 mg/day will be given when fertilization is confirmed. A pregnancy test will be done 2 weeks after embryo transfer. For patients with a positive pregnancy test, progesterone is to be continued for an additional 4 weeks. Clinical pregnancy will be defined as Visualization of an intrauterine gestational sac 5 weeks after embryo transfer.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria:

- Women undergoing IVF/ICSI treatment with expected poor ovarian response according to the Bologna criteria

Exclusion Criteria:

- Women with BMI >35 Kg/M2

- Women with a single ovary

- Known allergy to DHEA

- Diabetic women on insulin as insulin lowers DHEA levels and might reduce the effectiveness of DHEA supplements

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
DHEA


Locations

Country Name City State
Egypt Cairo University Hospitals Cairo
Egypt Dar AlTeb subfertility centre Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007 Dec;24(12):629-34. Epub 2007 Dec 11. — View Citation

Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 Oct;15(10):2129-32. — View Citation

Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19. — View Citation

Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol. 2011 Aug 17;9:116. doi: 10.1186/1477-7827-9-116. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical pregnancy Sonographic detection of a gestational sac 5 weeks after embryo transfer No
Secondary Number of oocytes retrieved one hour after ovum pick up No
Secondary Number of formed embryos 3 days after ovum pick up No
Secondary Quality of formed embryos 3 days after ovum pick up No
See also
  Status Clinical Trial Phase
Completed NCT03569787 - Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
Completed NCT03105453 - The Microbiome in Subfertility and Assisted Reproductive Technologies (ART)
Terminated NCT02180256 - Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial N/A
Terminated NCT02197832 - A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles N/A
Completed NCT00971152 - Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Phase 3
Completed NCT01569945 - Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur N/A
Recruiting NCT04064840 - GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET Phase 3
Recruiting NCT02561793 - DHEA Versus Placebo in Women With Poor Ovarian Response Phase 3
Terminated NCT02570386 - Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer N/A
Completed NCT02197208 - A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET N/A
Completed NCT01961336 - Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Phase 3
Completed NCT02487940 - Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure Phase 4
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A
Completed NCT00985062 - Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization N/A
Recruiting NCT04538560 - Preimplantation Genetic Testing for Aneuploidy of Polar Bodies N/A
Completed NCT02748278 - Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment
Completed NCT02044445 - Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval? N/A
Completed NCT02863614 - Analgesia for Endometrial Scratching N/A
Completed NCT02154958 - Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility N/A
Completed NCT01067664 - Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome N/A